Biostax (BTAX) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document And Entity Information
Entity Registrant Name	Immune Therapeutics, Inc.
Entity Central Index Key	1,559,356
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		434,322,060
Trading Symbol	IMUN
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 5,859	$ 14,718
Inventories	158,648	178,098
Total current assets	164,507	192,816
Fixed Assets:
Computer equipment, net of accumulated depreciation of $9,798 and $8,714 respectively	3,199	2,529
Investment in affiliate, equity method
Deposits	200	200
Total assets	167,906	195,545
Current Liabilities:
Accounts payable	1,532,878	2,319,932
Accounts payable, affiliate	22,582
Accrued liabilities	3,087,841	2,489,404
Notes payable, net of debt discount	4,795,298	4,820,063
Derivative liability	1,448,784	1,669,532
Total current liabilities	10,887,383	11,298,931
Total liabilities	10,887,383	11,298,931
Commitments and Contingencies (Note 12)
Stockholders' Deficit:
Common stock - par value $0.0001; 500,000,000 shares authorized; 415,661,456 and 386,782,473 shares issued and outstanding respectively	41,566	38,679
Additional paid in capital	369,427,460	366,625,144
Stock issuances due	78,259	103,226
Prepaid services		(226,667)
Accumulated deficit	(380,266,762)	(373,035,183)
Deficit attributable to common stockholders	(10,719,477)	(6,494,801)
Non-controlling interest		(4,608,585)
Total stockholders' deficit	(10,719,477)	(11,103,386)
Total liabilities and stockholders' deficit	$ 167,906	$ 195,545

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 9,798	$ 8,714
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	415,661,456	386,782,473
Common stock, shares outstanding	415,661,456	386,782,473

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues, net			$ 65,013
Cost of products sold			33,172
Gross profit			31,841
Operating expenses
Selling, general and administrative	587,726	620,905	2,346,090	1,842,778
Research and development expense		109,340	185,692	362,110
Stock issued for services G&A	62,500	446,002	716,075	1,537,292
Warrant valuation		272,707		590,605
Depreciation and amortization expense	217	269	1,084	557
Total operating expenses	650,443	1,449,223	3,248,941	4,333,342
Loss from operations	(650,443)	(1,449,223)	(3,217,100)	(4,333,342)
Other income (expense):
Interest expense	(408,507)	(118,878)	(870,479)	(822,789)
Loss on deconsolidation			(2,791,172)
Gain/(Loss) on derivative	(876,830)		(118,542)
Gain/(Loss) on settlement of debt	(666,632)	(31,741)	(684,668)	998,991
Total other income (expense)	(1,951,969)	(150,619)	(4,464,861)	176,202
Net income/(loss) before income taxes	(2,602,412)	(1,599,842)	(7,681,961)	(4,157,140)
Income taxes
Net income/(loss)	(2,602,412)	(1,599,842)	(7,681,961)	(4,157,140)
Net income/(loss) attributable to non-controlling interest		(217,574)	(450,382)	(485,656)
Net income/(loss) attributable to common shareholders	$ (2,602,412)	$ (1,382,268)	$ (7,231,579)	$ (3,671,484)
Basic and diluted loss per share attributable to common shareholders	$ (0.01)	$ 0	$ (0.02)	$ (0.01)
Weighted average number of shares outstanding	407,253,837	341,109,212	396,863,363	301,844,205

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock To Be Issued [Member]	Prepaid Services [Member]	Accumulated Deficit [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2017	$ 38,679	$ 366,625,144	$ 103,226	$ (226,667)	$ (373,035,183)	$ (4,608,585)	$ (11,103,386)
Balance, shares at Dec. 31, 2017	386,782,473
Issuance of common stock for services	$ 1,073	513,303	(24,967)
Issuance of common stock for services, shares	10,738,640
Amortization of prepaid services				226,667			226,667
Issuance of common stock in exchange for debt	$ 1,794	560,712					562,506
Issuance of common stock in exchange for debt, shares	17,940,343
Issuance of common stock for interest	$ 20	8,980					9,000
Issuance of common stock for interest, shares	200,000
Issuance of common stock for sale and exercise of warrants		240,500					240,500
Issuance and modification of common stock warrants		1,478,821					1,478,821
Elimination of Cytocom noncontrolling interest and deconsolidation						5,058,967	5,058,967
Net loss					(7,231,579)	(450,382)	(7,681,961)
Balance at Sep. 30, 2018	$ 41,566	$ 369,427,460	$ 78,259		$ (380,266,762)		$ (10,719,477)
Balance, shares at Sep. 30, 2018	415,661,456

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (7,681,961)	$ (4,157,140)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	1,084	557
Stock issued, and amortization of stock issued, for prepaid services	226,667	1,270,837
Gain/(Loss) on settlement of debt	684,668	(998,991)
Penalties related to note default	75,792
Stock issued for services	665,230	266,456
Stock warrant expense		590,605
Amortization of debt discount	274,777	60,347
Change in value of derivative	118,542
Expenses paid by lender	150,505
Loss on deconsolidation	2,791,172
Stock issued for interest	9,000	378
Changes in operating assets and liabilities:
Accounts payable	737,246	678,162
Accounts receivable
Inventories	19,450	(214,327)
Accrued liabilities	979,113	887,608
Due to Cytocom	23,771
Net cash used in operating activities	(924,944)	(1,615,508)
CASH FLOWS FROM INVESTING ACTIVITIES
Deconsolidation of subsidiary	(11,631)
Purchase of computer equipment	(1,754)	(1,505)
Net cash used in investing activities	(13,385)	(1,505)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of stock and exercise of warrants	240,500	706,540
Payment of notes payable		(321,846)
Proceeds from issuance of notes payable	688,970	1,180,500
Net cash provided by financing activities	929,470	1,565,194
Net increase (decrease) in cash	(8,859)	(51,819)
Cash and cash equivalents at beginning of period	14,718	74,389
Cash and cash equivalents at end of period	5,859	22,570
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	53,341	29,500
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount	243,000	50,000
Conversion of debt and accrued interest to common stock	692,640	3,051,969
Settlement of derivative liability	243,199
Deconsolidation of Cytocom, Inc.	2,278,237
Shares issued for accounts payable and accrued expenses		254,738
Cashless exercise of warrants		1,705
Estimated gain/(loss) on debt conversion		215,000
Increase in note due to default provisions	190,792
Increase in note due to new agreement	150,000
Reclassification from notes payable to accounts payable	40,628
Accounts payable paid directly by lender	150,505	273,821
Common stock issued for prepaid services		266,455
Settlement paid by lender		$ 150,000

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Immune Therapeutics, Inc. (the “Company”) was initially incorporated in Florida on December 2, 1993 as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all of the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. We filed our name change amendment with the Secretary of State of Florida on October 27, 2014 changing our name to Immune Therapeutics, Inc. The Company currently operates out of Orlando, Florida. In July 2012, the Company’s focus turned to acquiring patents that would protect and advance the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (“LDN”) and Methionine [Met5]-enkephalin (“MENK”). The Company’s therapies are believed to stimulate and/or regulate the immune system in such a way that they provide the potential to treat a variety of diseases. We believe our therapies may be able to correct abnormalities or deficiencies in the immune system in diseases such as HIV infection, autoimmune disease, immune disorders, or cancer; all of which can lead to disease progression and life-threatening situations when the immune system is not functioning optimally. In October 2012, the Company formed TNI BioTech International, Ltd., a BVI company in Tortola, British Virgin Islands, which was set up to allow the Company to market and sell LDN in those countries outside the U.S. in which we have been able to obtain approval to sell the Company’s products. In August 2013, the Company formed its United Kingdom subsidiary, TNI BioTech, LTD (the “UK Subsidiary”). The UK Subsidiary received approval to be considered a micro, small or medium-sized enterprise (“SME”) with the European Medicines Agency (“EMA”) on August 21, 2013. The designation provides the UK Subsidiary with significant discounts when holding meetings or submitting filings to the EMA. On September 19, 2013, the UK Subsidiary submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the UK Subsidiary a meeting that took place on September 27, 2013. The UK Subsidiary is eligible to benefit from the provisions for administrative and financial assistance for SMEs set out in Regulation (EC) No 2049/2005. The Company will apply to obtain EMA benefits once funding becomes available. In December 2013, the Company formed a subsidiary, Cytocom Inc. (“Cytocom”), to focus on conducting LDN and MENK clinical trials in the United States. In December 2014, the Company finalized the distribution of common stock of Cytocom to its shareholders. As part of the transaction (“Original Agreement”), the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On December 8, 2014, the number of Cytocom shares of common stock that were issued to our shareholders totaled 113,242,522 shares. In connection with the above-mentioned transaction to transfer intellectual property to Cytocom, Cytocom issued an additional 140,100,000 shares of its common stock to the Company, which gave the Company a 55.3% stake in Cytocom on that date. In April 2016, the Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom’s outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement. Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis. The Restated Agreement was a condition of the Stock Agreement. At September 30, 2018, the Company’s equity interest in Cytocom stood at 15.95% of Cytocom’s common stock issued and outstanding on that date. The Company’s policies with respect to accounting for its equity interest in Cytocom is described in Note 2 to the “Notes to the Condensed Consolidated Financial Statements” below (“Summary of Significant Accounting Policies: Non-Controlling Interest in Consolidated Subsidiaries”). In March 2014, the Company incorporated Airmed Biopharma Limited, an Irish corporation with an address in Dublin, Ireland, and Airmed Holdings Limited, an Irish company domiciled in Bermuda. The Irish companies were set up to benefit from incentives granted by the Irish government for the establishment of pharmaceutical companies (many of the world’s leading pharmaceutical companies have located in Ireland), and so that the Company could take advantage of Ireland’s status as a member of the European Union and the European Economic Area. An Irish limited liability company enjoys a low corporate income tax rate of 12.5%, one of the lowest in the world. The Irish-domiciled company hopes to qualify for tax incentives for Irish holding/headquartered companies and to benefit from the network of double tax treaties that reduce withholding taxes. TNI BioTech International, Ltd. will manage our international distribution, using product that is manufactured in Ireland and elsewhere. Today, the Company is a clinical late-stage T-Cell Activation biopharmaceutical company focused on the development immunotherapies for the treatment of autoimmune and inflammatory conditions, cancer, HIV/AIDS and animal diseases on a global basis. As of this date, neither we nor our collaboration partners are permitted to market our drug candidates in the United States until we receive approval of a New Drug Application from the FDA. Neither we nor our collaboration partners have submitted an application for or received marketing approval for any of our drug candidates. Obtaining approval of an NDA can be a lengthy, expensive and uncertain process. Going Concern The Company experienced a net loss from operations of $650,443, and used cash and cash equivalents for operations in the amount of $924,944 during the quarter ended September 30, 2018, resulting in stockholder’s deficit of $380,266,762 at that date. The Company has incurred significant net losses since inception and has relied on its ability to fund its operations through private equity financings. Management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its product candidate and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through the sale of products, additional private or public debt or equity offerings, and it may also seek additional capital through arrangements with strategic partners or from other sources. Based on the Company’s operating plan, existing working capital at September 30, 2018 was not sufficient to meet the cash requirements to fund planned operations for the next 12 months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2017 (including the notes thereto) set forth in Form 10-K. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2017. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At September 30, 2018, the Company’s equity interest in Cytocom stood at 15.95% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. The condensed consolidated financial statements as of September 30, 2018 exclude the assets, liabilities and operating results of Cytocom after May 1, 2018. Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. We believe the new standard will not have a material impact on our consolidated financial position and consolidated results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions once we commence revenue-generating activities. Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2018, the Company had no cash balances in excess of insured limits. Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments” Fair Value Measurements The ASC Topic 820, Fair Value Measurement, Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the three months ended September 30, 2018 and September 30, 2017 was $217 and $269 respectively. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses. Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of September 30, 2018 and 2017, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2018, and 2017, the Company has not accrued any interest or penalties related to uncertain tax positions. In February 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic net loss per share follows: For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Net Profit/(Loss) $ (2,602,412 ) $ (1,382,268 ) $ (7,681,961 ) $ (3,671,484 ) Weighted-average common shares outstanding Basic and diluted: 407,253,837 341,109,212 396,863,363 301,844,205 Profit/(Loss) per share outstanding Basic and diluted $ (0.01 ) $ (0.00 ) $ (0.02 ) $ (0.01 ) The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Recent Accounting Standards During the quarter ended September 30, 2018, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2018
Fixed Assets:
Fixed Assets	3. Fixed Assets September 30, 2018 December 31, 2017 Fixed Assets: Computer equipment $ 12,997 $ 11,243 Less accumulated depreciation (9,798 ) (8,714 ) Fixed assets, net $ 3,199 $ 2,529 The Company utilizes the straight-line method for depreciation, using three to five-year depreciable asset lives. Depreciation expense was not material for all periods presented.

Investments_ Deconsolidation of

Investments: Deconsolidation of Cytocom	9 Months Ended
	Sep. 30, 2018
Investments Deconsolidation Of Cytocom
Investments: Deconsolidation of Cytocom	4. Investments: Deconsolidation of Cytocom In accordance with the May 1, 2018 “Restated Agreement” with Cytocom, the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. Accordingly, effective May 1, 2018, the Company deconsolidated Cytocom. However, the Company exercises influence through its retained equity interest and through representation on Cytocom’s board of directors. As a result, the Company uses the equity method to account for its retained interest in Cytocom On May 1, 2018, the Company recorded an equity method investment in Cytocom of $1,189, the par value of Cytocom common stock multiplied by the number of shares owned by the Company, due to the negative equity associated with Cytocom’s underlying financial position. As a result of the continuing losses in Cytocom, the balance of this investment is currently $0. At September 30, 2018, Cytocom had no significant assets or income. Cytocom notes payable on that date aggregated $1,193,500.

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Accrued Liabilities	5. Accrued Liabilities Accrued expenses and other liabilities consist of the following: September 30, 2018 December 31, 2017 Accrued payroll to officers and others 2,212,393 1,539,777 Accrued interest and penalties - notes payable 738,878 703,141 Estimated legal settlements 136,057 136,057 Other accrued liabilities 23,095 393 Estimated loss on note conversions - 110,036 Derivative Liability 1,448,784 1,669,532 Total accrued expenses and other liabilities $ 4,559,207 $ 4,158,936

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable Notes payable consist of the following: September 30, 2018 December 31, 2017 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of September 30, 2018, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at September 30, 2018, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $475,994 were in default at September 30, 2018, as the Company was unable to repay those notes on their due dates. $130,000 of the notes were deconsolidated on May 1, 2018 and $100,000 of the notes along with $150,000 of interest were extinguished in July 2018. 475,994 705,994 Promissory notes issued by Cytocom between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on December 31, 2016. At September 30, 2018, the notes were in default. These notes were deconsolidated on May 1, 2018. - 425,000 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. 97,737 97,737 Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. This note was extinguished on July 1, 2018. 50,000 Promissory note for $180,000 was issued in July 2016 with an original issue discount of $30,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. Under the terms of the note, the principal amount was increased in 2017 to $243,000, and interest accrued at 25% per annum. $161,976 of principal and $20,025 of accrued interest were converted into 7,447,448 shares, of which 5,500,000 shares were issued at the end of 2017. The Company has accrued a $243,199 derivative liability for the $81,024 principal balance attributable to the conversion feature contained in this note. The note was settled in the quarter ended March 31, 2018. - 81,024 Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,642. The note was in default on September 30, 2018. The balance due was reclassified as accounts payable. - 17,284 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at September 30, 2018 the notes were in default. 206,000 206,000 Notes aggregating $1,354,000 issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As of September 30, 2018 the notes were in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018. At September 30, 2018, the notes were in default. 500,000 500,000 Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017 and at September 30, 2018 the note was in default. 50,000 50,000 Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At September 30, 2018, the notes were in default. 300,000 300,000 Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At September 30, 2018, $50,000 of the notes were in default. 191,800 191,800 Promissory note for $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at September 30, 2018 had increased to $500,792. $115,000 of accrued interest owed on the note has been converted to stock. The Company has accrued a $1,448,784 derivative liability for the remaining conversion right. 500,792 425,000 Notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum and mature on December 31, 2018. 105,500 105,500 Notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At September 30, 2018, $10,000 of the notes were in default. 47,975 - Notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.005. At September 30, 2018, the notes were in default. 125,000 - Notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest of 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At September 30, 2018, the notes were in default. 65,000 - Notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. 193,000 - In July 2017, a note for $250,000 was issued. The note earns interest at 5% per annum and matures on November 1, 2018. 250,000 - Less: Original issue discounts on notes payable and warrants issued with notes. (53,500 ) (75,277 ) Total $ 4,795,298 $ 4,820,062 As of September 30, 2018, the Company had accrued $738,878 in unpaid interest and default penalties. During the quarter ended September 30, 2018, 9,333,143 shares with a fair value of $111,091 were issued by the Company for settlement of promissory notes totaling $60,000. As of September 30, 2017, the Company had accrued $594,875 in unpaid interest and default penalties. During the quarter ended September 30, 2017, 4,694,017 shares with a fair value of $138,843 were issued or reserved for issuance by the Company for settlement of promissory notes.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	7. Derivative Liabilities During the quarter ended September 30, 2018, no notes payable were issued as convertible debt or became convertible and qualified as a derivative liability under FASB ASC 815. In the quarter, notes payable with a derivative liability of $60,000 were converted, and the derivative liability on other notes payable was revalued from $623,045 to $1,448,784. As of September 30, 2018, and December 31, 2017, the aggregate fair value of the outstanding derivative liability was $1,448,784 and $1,669,532 respectively. The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the quarter ended September 30, 2018: Three months ended September 30, Volatility 248 % Risk-free interest rate 1.81 % Expected dividends - % Expected term 1 year The Company determines the fair market values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company uses Level 3 inputs to estimate the fair value of its derivative liabilities. The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of September 30, 2018: Fair Value Measurements as of September 30, 2018 Level 1 Level 2 Level 3 Assets None $ - $ - $ - Total assets - - - Liabilities Conversion option derivative liability - - 1,448,784 Total liabilities $ - $ - $ 1,448,784 The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Inputs (Level 3) Beginning balance $ 1,669,532 Settlement of liability (243,199 ) Partial settlement of liability (96,091 ) Change in fair value (118,542 ) Ending balance $ 1,448,784

Capital Structure - Common Stoc

Capital Structure - Common Stock and Common Stock Purchase Warrants	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Capital Structure - Common Stock and Common Stock Purchase Warrants	8. Capital Structure—Common Stock and Common Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. As of September 30, 2018 and 2017, the Company was authorized to issue 500,000,000 common shares at a par value of $0.0001 per share. As of September 30, 2018, the Company had 415,661,456 shares of common stock outstanding, and 386,782,473 outstanding as of December 31, 2017. Stock Warrants In the quarter ended September 30, 2018, there were 80,550,000 new warrants issued by the Company. There were no modifications of the terms of any warrants issued by the Company in the quarters ended September 30, 2018 and 2017. Following is a summary of outstanding stock warrants at September 30, 2018 and activity during the three months then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2017 84,287,402 $ 0.01-15.00 $ 0.33 Issued in 2018 141,620,636 $ 0.005-0.20 $ 0.16 Expired and forfeited 410,834 $ 1.50-15.00 $ 6.79 Exercised - $ - - Warrants as of September 30, 2018 225,497,204 $ 0.01-15.00 $ 0.14 Summary of outstanding warrants as of September 30, 2018: Expiration Date Number of Shares Exercise Price Remaining Life (years) Fourth Quarter 2018 6,089,166 $ 1.00-1.50 .25 First Quarter 2019 4,024,000 $ 0.50-2.00 .50 Second Quarter 2019 135,000 $ 0.07-0.23 .75 Third Quarter 2019 260,000 $ 0.50-1.50 1.00 Fourth Quarter 2019 22,690,908 $ 0.05-3.74 1.25 Second Quarter 2020 300,000 $ 0.50 1.75 Fourth Quarter 2020 1,000,000 $ 0.20 2.25 First Quarter 2021 12,600,000 $ 0.20 2.50 Second Quarter 2021 5,812,252 $ 0.01-0.20 2.75 Third Quarter 2021 5,116,667 $ 0.03-0.20 3.00 Fourth Quarter 2021 300,000 $ 0.10 3.25 Second Quarter 2022 1,750,000 $ 0.15 3.75 Third Quarter 2022 2,650,000 $ 0.05-0.10 4.00 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 4.25 First Quarter 2023 700,000 $ 0.01-0.03 4.50 Second Quarter 2023 15,000,000 $ 0.01-0.20 4.75 Third Quarter 2023 76,100,000 $ 0.01-0.10 5.00 First Quarter 2024 30,000,000 $ 0.01 5.50 Third Quarter 2028 3,000,000 $ 0.07 10.00 Second Quarter 2032 21,807,789 $ 0.01-0.07 13.75 225,497,204 $ 0.01-15.00

Stock Compensation

Stock Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Compensation	9. Stock Compensation Shares Issued for Services During the quarters ended September 30, 2018 and 2017, the Company issued 7,500,000 and 1,700,000 shares of common stock respectively for consulting fees. The Company valued these shares at $190,000 and $61,000 respectively, based upon the fair market value of the common stock at the dates of the agreements. The consulting fees are amortized over the contract periods, which are typically between 12 and 24 months. The amortization of prepaid services totaled $0 and $446,002 for the quarters ended September 30, 2018 and 2017.

Income Taxes - Results of Opera

Income Taxes - Results of Operations	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes - Results of Operations	10. Income Taxes - Results of Operations There was no income tax expense reflected in the results of operations for the quarters ended September 30, 2018 and 2017 because the Company incurred a net loss in both quarters. On December 22, 2017, the President of the United States signed the Tax Cuts and Jobs Act (“U.S. Tax Reform”), which enacts a wide range of changes to the U.S. corporate income tax system. The impact of U.S. Tax Reform primarily represents the Company’s estimates of revaluing the Company’s U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%, effective for the 2018 tax year. Based on the Company’s historical financial performance, at December 31, 2017, the net deferred tax asset position was re-measured at the lower corporate rate of 21% and a tax expense was recognized to adjust net deferred tax assets to the reduced value. Deferred tax assets: September 30, 2018 December 31, 2017 Net operating losses $ 21,319,000 $ 18,102,000 Stock based compensation 39,568,000 39,054,000 Amortization, depreciation, and impairment 4,179,300 4,178,000 Capitalization of start-up costs for tax purposes 1,145,000 1,145,000 Loss on debt conversion of debt 569,000 569,000 Total deferred tax assets 66,780,300 63,048,000 Valuation allowance (66,780,300 ) (63,048,000 ) Total deferred tax assets, net $ - $ - The Company has recognized no tax benefit for the losses generated for the periods through September 30, 2018. ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided. Our effective tax rate for fiscal years 2018 and 2017 was 0%. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year, but are not consistent from year to year. At December 31, 2017, we had estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $86,000,000, which will expire in 2032-2037. 2018 2017 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 212,000 21 % $ 874,000 34 % Permanent differences 173,000 17 % 137,000 - Change in estimates (385,000 ) - (1,011,000 ) - $ - - % $ - - %

Licenses and Supply Agreements

Licenses and Supply Agreements	9 Months Ended
	Sep. 30, 2018
Licenses And Supply Agreements
Licenses and Supply Agreements	11. Licenses and Supply Agreements Patent and Subsidiary Acquisition The Company entered into a share exchange agreement on April 24, 2012 to acquire all of the outstanding shares of TNI BioTech IP, Inc. (“TNI IP”), a biotechnology firm incorporated in Florida and formed to acquire patents related to the treatment of cancer and HIV/AIDS and autoimmune diseases, using Met-enkephalin (“MENK”) and Naltrexone (“LDN”). The goal of TNI IP’s management was to enable mankind and civilization to combat fatal diseases by activating and mobilizing the body’s own immune system using TNI IP’s patented use of MENK. The first patents acquired by TNI IP were acquired from Dr. Nicholas P. Plotnikoff and Professor Fengping Shan in 2012. TNI IP was acquired in exchange for 20,250,000 shares of the Company’s common stock, of which 8,000,000 shares were issued to Dr. Plotnikoff for the acquisition of patents and the remaining 12,250,000 shares were issued to the founders of TNI IP in exchange for all of their right, title and interest in their TNI IP shares. The goodwill arising on the acquisition of TNI BioTech IP, Inc. was valued at $98,000,000 and license agreements arising from the acquisition of TNI IP were valued at $16,006,000. All of these balances were subsequently impaired during prior periods. In connection with the share exchange, we entered into a Sale of Technology Agreement with Dr. Nicholas P. Plotnikoff on March 4, 2012, wherein Dr. Plotnikoff agreed to transfer and assign all of his rights, title and interest in: European Patent United Kingdom, Germany, France, Ireland EP 1401471 BI Methods for inducing sustained immune response; Russian Patent Russian Federation patent number 2313364; The Patent Office of the People’s Republic of China, Application No.: 200810165784.8 China Patent CN1015113407 A The Patent Office of the People’s Republic of China ISSN: 1006-2858 CN 21-1349/R; Patent Agencies Government of India Patent, Application number 1627/KOLNP/2003 number 220265 an Enkephalin Peptide Composition; and the US Patent Pending, US Patent Application 10/146.999 e. The Company received all the production formulations and technology designs from Dr. Plotnikoff necessary for the manufacturing, formulation, production and protocols of the MENK treatment of cancer and HIV/AIDS. As consideration for entering into the Sale of Technology Agreement, Dr. Plotnikoff received 8,000,000 shares of common stock, a royalty of a single-digit percentage on all sales of MENK and was granted the position of Non-Executive Chairman of the Board of Directors. At the time of the acquisition, the valuation of goodwill and other intangible assets were determined using the fair market price for the Company’s common stock, which were exchanged for shares of TNI IP. In the fourth quarter of 2012, the Company performed an annual valuation to determine whether any goodwill or intangible assets that had been acquired by the Company were impaired. The result of this valuation was that material impairments were identified. In 2014, the Company recognized an impairment of the goodwill arising on the acquisition of TNI IP of $98,000,000. Patent License Agreements In December 2014, the Company transferred to Cytocom certain of its rights, title and interest in or relating to intellectual property (i) patents, patent applications, and all divisional, continuations and continuations-in-part thereof, together with all reissues, reexaminations, renewals and extensions thereof and all rights to obtain such divisionals, continuations and continuations-in-part, reissues, reexaminations, renewals and extensions, and all utility models and statutory invention registrations and any other such analogous rights, (ii) trademarks, service marks, Internet domain names, trade dress, trade styles, logos, trade names, services names, brand names, corporate names, assumed business names and general intangibles and other source identifiers of a like nature, together with the goodwill associated with any of the foregoing, and all registrations and applications for registrations thereof, together with all renewals and extensions thereof and all rights to obtain such renewals and extensions, (iii) copyrights, mask work rights, database and design rights, moral rights and rights in Internet websites, whether registered or unregistered and whether published or unpublished, all registrations and recordings thereof and all applications in connection therewith, together with all renewals, continuations, reversions and extensions thereof and all rights to obtain such renewals, continuations, reversions and extensions, and (iv) confidential and proprietary information, including, trade secrets and know-how. Cytocom licensed back to the Company a perpetual, non-exclusive, royalty-free right and license to use the assigned intellectual property for veterinary indications and for the marketing rights to emerging markets, access to all clinical data, use of the formulation for LDN and MENK. The Original Agreement also granted the Company rights to market Lodonal™ and Met-Enkephalin (“MENK”) in “Emerging Markets,” which included all countries excluding Canada, Italy, Japan, France, Germany, United Kingdom, European Community and the United States. Pursuant to the Original Agreement, the Company was required to pay Cytocom a 5% royalty on all sales all ongoing drug development and fees due in connection with the underlying patents until such time as Cytocom was funded. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom. The Restated Agreement restates the licensing arrangement between the Company and Cytocom as provided by the Original Agreement. The Restated Agreement grants the Company distribution and marketing rights for Lodonal™ and MENK for humans in Emerging Markets. In addition, the Company has been granted the rights to distribute and market Lodonal™ and MENK for animal use in the United States. The royalty due to Cytocom has been reduced from 5% to 1% of sales and the Company no longer has any ongoing obligations to pay for the cost in connection with the assets of Cytocom.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Malawi Treatment Facilities On July 14, 2012, GB Oncology and Imaging Group LTD (“GBOIG”) in partnership with the Company signed a letter of intent agreement to collaborate with the Government of Malawi to assist in expanding the treatment of cancer, HIV/AIDS and other infectious diseases. In December of 2014, the Government of Malawi completed an oncology clinic at the Queen Elizabeth Central Hospital in Blantyre, Malawi for the treatment of cancer and infectious diseases. In 2015, the Company submitted protocols seeking permission from the Pharmacy, Medicines and Poisons Board of Malawi (“PMPB”) to conduct a trial involving Lodonal™ in Malawi: a. The first protocol, submitted jointly with The Jack Brewer Foundation (“JBF Worldwide”), received PMPB approval on November 11, 2015. The protocol covers a 12-month trial for a “Single Visit Approach to Cervical Cancer Prevention.” The approach is designed to deliver a preventive and simple procedure that can be performed in a clinical setting without the use of a laboratory and to allow for immediate treatment of any precancerous lesions utilizing Wallach LL100 Cryosurgical systems. The protocol provides for 50% of the patient group to be put on Lodonal™ to determine if the drug lowers the number of opportunistic infections during the year, and if it can be shown that LDN increases CD4, CE8, NK and T cell count, which would show that the incidence rates of opportunistic infection could decrease with Lodonal™ and that Lodonal™ could be used as a prophylaxis to prevent substantial HIV-related morbidity in Malawi. The PMPB approved the trial in late 2016, recruitment began in late 2016 and the trial is now ongoing. The trial has had problems with recruitment and continues today. b. The second protocol, which has not yet been approved, covers a trial using Lodonal™ for the treatment of cancer. The Company has put this trial on hold as it may not be necessary with the approval in Nigeria in addition to the pending approval in Kenya and Senegal for Lodonal™ for the treatment of cancer. Distribution Agreements in Nigeria In October 2013, the Company announced the signing of a Distribution Agreement with AHAR Pharma, a Nigerian company, to market Lodonal™, in Nigeria for the treatment of autoimmune diseases and cancer. AHAR intends to distribute Lodonal™ through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria. The first deliveries under the agreement took place in February 2018. Under the original agreement, the Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma’s first-year purchase commitment. Due to the fact that AHAR Pharma failed to meet its contractual purchase obligations, the Company formally issued notice of default under the agreement. On April 18, 2018, AHAR Pharma transferred its rights under the Distribution Agreement to Fidson Healthcare Plc (“Fidson”), and Fidson signed an exclusive distribution agreement with the Company to distribute Lodonal™. In October 2018, the Company shipped 250,000 pills to Fidson to support the product launch in the coming months. Agreements with Hubei Qianjiang Pharmaceutical Company On October 18, 2012, the Company and Hubei Qianjiang Pharmaceutical Co., Ltd. (“Qianjiang Pharmaceutical”), signed a Venture Cooperation Agreement on New Drug Methionine Enkephalin (the “Venture Agreement”) pursuant to which Qianjiang Pharmaceutical acquired an exclusive license for the production of MENK in China. The Venture Agreement requires that Qianjiang Pharmaceutical conduct drug research and pilot testing for MENK, organize pre-clinical studies, and apply for clinical trials for MENK with the Chinese State Food and Drug Administration. The Venture Agreement was amended on February 24, 2013 to expand the clinical trials from pancreatic to both pancreatic and liver cancer and amended on March 6, 2014 to require Qianjiang Pharmaceutical to commence studies and clinical trials in China and place funds in the co-administration account. On August 6, 2014, the Company entered into a Supplementary Agreement on New Drug Methionine – Enkephalin Cooperation (the “Amendment”) with Qianjiang Pharmaceutical, amending the Venture Agreement, as amended. The Company and Qianjiang Pharmaceutical executed the Amendment to accelerate clinical trials in both the United States and China, and agreed to immediately initiate three month Good Laboratory Practice (“GLP”) Toxicology Studies (rat and dog) within 30 days of signing the Amendment. The Amendment requires that the GLP Toxicology Studies Trials are conducted in China in accordance with international standards and standards acceptable to the FDA. In February 2013, the Company signed a Strategic Framework Agreement for Cooperation with Qianjiang Pharmaceutical. Under the agreement, the parties will work together to further the development of new products and conduct research and development on the Company’s licensed patented technology. Specifically, the parties aim to co-invest to develop and market products focusing on HIV, cancer and related autoimmune system therapies, develop co-ventured manufacturing facilities in China, and develop co-ventured distribution of the developed products in China and Africa. The agreement does not have a definitive term, as each new agreement resulting from the cooperation will set forth the material terms, including, but not limited to, fees, duration and termination therein. In December of 2016 Qianjiang Pharmaceutical delivered various documents under the agreements related to its studies of Exploratory Toxicology (nGLP) and Definitive Toxicology (GLP). In addition to the pharmacology and toxicology studies, Qianjiang Pharmaceutical and China Peptide completed the formulation and CMC necessary to scale up manufacturing of MENK. There has been no progress under the agreements in the past 12 months, since a change of ownership of Qianjiang Pharmaceutical in 2017. The Company continues to hold discussions with new management about the future of the agreements. Contract Manufacturing Agreements On May 16, 2016, the Company entered into an agreement with Complete Pharmacy and Medical Solutions, LLC (“CPMS”) to compound, package and distribute the LDN tablets, capsules and/or creams in the United States. The initial term of the agreement is three years, with the option to renew for an additional year. The agreement may be terminated by (i) mutual agreement, (ii) in the event of a breach, provided however that if the Company terminates the agreement, the Company will be required to reimburse CPMS for all unused packaging materials for the LDN, which unused packaging materials CPMS will provide to IMUN. If CPMS does not receive and ship at least 1,000 orders (prescriptions) during the term of the agreement, the Company will be required to reimburse CPMS for 100% of the “ramp up costs” (defined as all costs and expenses of labor and materials related to the testing, and required FDA and other governmental documentation/approvals of test data) of providing and producing the LDN, even where the Company cancels/terminates the agreement, which provision shall survive the cancellation/termination of the agreement. On October 25, 2016, the Company and Acromax Dominicana, SA (“Acromax”), which is based in the Dominican Republic, entered into a contract for manufacturing of LDN tablets, capsules and/or creams (“Agreement”). Subject to the terms and conditions of the Agreement, Acromax will obtain all necessary licenses and permits to carry out the manufacturing and packaging of LDN in exchange for a fixed fee per tablet plus an additional fee for packaging, shipping and customs clearance. The Agreement has an initial term of five years unless terminated by either party in accordance with the terms. Operating Leases At September 30, 2018, the Company was a party to an agreement to lease office space in Orlando, Florida. Rental expense for the three months ended September 30, 2018 and 2017 was $2,238 and $12,632 respectively. Legal Proceedings None.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company issued 18,661,118 shares of common stock between September 30, 2018 and November 14, 2018. 12,411,118 shares were for debt conversions and 6,250,000 were for consulting fees. As of November 14, 2018, the Company had outstanding 434,322,060 shares of common stock. Between September 30, 2018 and November 14, 2018 the company raised $15,500 in debt and equity financing. On August 7, 2018, the Company announced that Dr. Roscoe Moore Jr., DVM, MPH, Ph.D., DSc joined the Company as Chairman of the Board, and will also maintain a position on the Company’s Scientific Advisory Board. On September 6, 2018, the Company announced that Mr. Jack Brewer, MBA, joined the Company as a member of the Board of Directors.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2017 (including the notes thereto) set forth in Form 10-K. The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue for the year ended December 31, 2017. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.
Non-Controlling Interest in Consolidated Subsidiaries	Non-Controlling Interest in Consolidated Subsidiaries Prior to May 1, 2018, the Company consolidated Cytocom. On May 1, 2018, the Company entered into an amended and restated licensing agreement (the “Restated Agreement”) with Cytocom, Inc., in accordance with which the Company no longer has any ongoing obligations to pay for costs in connection with the assets of Cytocom. On June 4, 2018, the Company and Cytocom entered into a Stock Purchase Agreement (the “Stock Agreement”). Pursuant to the Stock Agreement, the Company cancelled approximately $4,000,000 of debt owed to it by Cytocom in exchange for ten percent (10%) of the issued and outstanding common stock of Cytocom, as calculated on a fully diluted basis on June 4, 2018. At September 30, 2018, the Company’s equity interest in Cytocom stood at 15.95% of Cytocom’s common stock issued and outstanding. Accordingly, the Company deconsolidated Cytocom as of May 1, 2018, and accounts for its retained interest in Cytocom under the equity method of accounting, with the Company’s share of Cytocom’s earnings recorded in “loss from equity method investment” in the consolidated statements of operations. The condensed consolidated financial statements as of September 30, 2018 exclude the assets, liabilities and operating results of Cytocom after May 1, 2018.
Revenue Recognition	Revenue Recognition We recognize revenue on sales to customers and distributors upon satisfaction of our performance obligations when the goods are shipped. For consignment sales, we recognize revenue when the goods are pulled from consignment inventory. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This standard provides a single set of guidelines for revenue recognition to be used across all industries and requires additional disclosures. It is effective for annual and interim reporting periods beginning after December 15, 2017. We believe the new standard will not have a material impact on our consolidated financial position and consolidated results of operations, as we do not expect to change the manner or timing of recognizing revenue on a majority of our revenue transactions once we commence revenue-generating activities.
Leases	Leases In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This standard requires all leases that have a term of over 12 months to be recognized on the balance sheet with the liability for lease payments and the corresponding right-of-use asset initially measured at the present value of amounts expected to be paid over the term. Recognition of the costs of these leases on the income statement will be dependent upon their classification as either an operating or a financing lease. Costs of an operating lease will continue to be recognized as a single operating expense on a straight-line basis over the lease term. Costs for a financing lease will be disaggregated and recognized as both an operating expense (for the amortization of the right-of-use asset) and interest expense (for interest on the lease liability). This standard will be effective for our interim and annual periods beginning January 1, 2019, and must be applied on a modified retrospective basis to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Early adoption is permitted. We are currently evaluating the timing of adoption and the potential impact of this standard on our financial position, but we do not expect it to have a material impact on our results of operations.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000. At September 30, 2018, the Company had no cash balances in excess of insured limits.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “ Financial Instruments”
Fair Value Measurements	Fair Value Measurements The ASC Topic 820, Fair Value Measurement,
Inventory	Inventory Inventories comprise finished product, raw materials and materials used for packaging. Inventories are stated at the lower of cost or market with cost based on the first-in, first-out (FIFO) method. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical trials or clinical manufacturing campaigns. Inventory used in marketing activities is charged to selling, general and administrative expense.
Fixed Assets	Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to five years. Maintenance and repairs are charged against expense as incurred. Depreciation expense for the three months ended September 30, 2018 and September 30, 2017 was $217 and $269 respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or change in circumstances indicate that the carrying amount of an asset may not be recoverable as prescribed by ASC Topic 360-10-05, “ Property, Plant and Equipment
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of salaries and benefits, pre-clinical studies, clinical trial activities, drug development and manufacturing, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf and third-party service fees, including clinical research organizations and investigative sites. Costs for certain development activities, such as clinical trials are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as operating expenses.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of September 30, 2018 and 2017, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of September 30, 2018, and 2017, the Company has not accrued any interest or penalties related to uncertain tax positions. In February 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors, including employee stock options, based on estimated fair values equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 505-50, “ Equity-Based Payments to Non-Employees
Net Loss Per Share of Common Stock	Net Loss per Share of Common Stock Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. Dilutive common stock equivalents are comprised of common stock purchase warrants and options outstanding. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. A calculation of basic net loss per share follows: For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Net Profit/(Loss) $ (2,602,412 ) $ (1,382,268 ) $ (7,681,961 ) $ (3,671,484 ) Weighted-average common shares outstanding Basic and diluted: 407,253,837 341,109,212 396,863,363 301,844,205 Profit/(Loss) per share outstanding Basic and diluted $ (0.01 ) $ (0.00 ) $ (0.02 ) $ (0.01 ) The Company’s potential dilutive securities which include warrants (as described in Note 8 to the Financial Statements – “Capital Structure – Common Stock and Common Stock Purchase Warrants”), have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share.
Recent Accounting Standards	Recent Accounting Standards During the quarter ended September 30, 2018, there were several new accounting pronouncements issued by the Financial Accounting Standards Board. Each of these pronouncements, as applicable, has been or will be adopted by the Company. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Basic Net Loss Per Share	A calculation of basic net loss per share follows: For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Net Profit/(Loss) $ (2,602,412 ) $ (1,382,268 ) $ (7,681,961 ) $ (3,671,484 ) Weighted-average common shares outstanding Basic and diluted: 407,253,837 341,109,212 396,863,363 301,844,205 Profit/(Loss) per share outstanding Basic and diluted $ (0.01 ) $ (0.00 ) $ (0.02 ) $ (0.01 )

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Fixed Assets:
Schedule of Fixed Assets	September 30, 2018 December 31, 2017 Fixed Assets: Computer equipment $ 12,997 $ 11,243 Less accumulated depreciation (9,798 ) (8,714 ) Fixed assets, net $ 3,199 $ 2,529

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses and other liabilities consist of the following: September 30, 2018 December 31, 2017 Accrued payroll to officers and others 2,212,393 1,539,777 Accrued interest and penalties - notes payable 738,878 703,141 Estimated legal settlements 136,057 136,057 Other accrued liabilities 23,095 393 Estimated loss on note conversions - 110,036 Derivative Liability 1,448,784 1,669,532 Total accrued expenses and other liabilities $ 4,559,207 $ 4,158,936

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consist of the following: September 30, 2018 December 31, 2017 Promissory note issued July 29, 2014 to Ira Gaines. In 2016, the maturity date on the note was extended to December 1, 2017. As of September 30, 2018, the note is in default. The note earns interest at a rate of 18% per annum. $ 100,000 $ 100,000 Promissory notes issued between November 26, 2014 and December 31, 2015, to raise up to $2,000,000 in debt. Lenders earn interest at a rate of 10% per annum, plus a pro-rata share of two percent of the Company’s gross receipts for sales of IRT-103-LDN in perpetuity. Notes will be repaid in 36 monthly installments of principal and interest commencing no later than October 15, 2015. These notes were in default at September 30, 2018, as the Company was unable to pay installments on their due dates. 286,000 286,000 Promissory notes issued between May 1, 2015 and December 31, 2016, and maturing between June 14, 2015 and December 1, 2017. Lenders on loans aggregating $375,994 earn interest at rates between 2% and 18% per annum. On loans aggregating $100,000, interest is payable in a fixed amount not tied to a specific interest rate. Notes aggregating $475,994 were in default at September 30, 2018, as the Company was unable to repay those notes on their due dates. $130,000 of the notes were deconsolidated on May 1, 2018 and $100,000 of the notes along with $150,000 of interest were extinguished in July 2018. 475,994 705,994 Promissory notes issued by Cytocom between April 29, 2015 and December 31, 2015. Lenders earn interest at rates between 5% and 10% per annum. These notes mature on December 31, 2016. At September 30, 2018, the notes were in default. These notes were deconsolidated on May 1, 2018. - 425,000 Promissory notes issued to an officer of the Company effective November 3, 2015 and maturing November 3, 2016 for settlement of accrued payroll, bearing interest at 10% per annum and including a stock conversion feature. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. 97,737 97,737 Promissory note issued in July 2016. The note was repayable on October 5, 2016 but was extended to December 31, 2016. The note earns interest at 6% per month. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. This note was extinguished on July 1, 2018. 50,000 Promissory note for $180,000 was issued in July 2016 with an original issue discount of $30,000. The note is repayable on April 7, 2017. The Company was unable to repay the note at maturity and at September 30, 2018 the note was in default. Under the terms of the note, the principal amount was increased in 2017 to $243,000, and interest accrued at 25% per annum. $161,976 of principal and $20,025 of accrued interest were converted into 7,447,448 shares, of which 5,500,000 shares were issued at the end of 2017. The Company has accrued a $243,199 derivative liability for the $81,024 principal balance attributable to the conversion feature contained in this note. The note was settled in the quarter ended March 31, 2018. - 81,024 Promissory notes issued in August 2016 for $149,854 as a settlement of amounts owed to a law firm. The notes accrue interest at 5% per annum and are payable in 18 equal monthly installments of $8,642. The note was in default on September 30, 2018. The balance due was reclassified as accounts payable. - 17,284 Promissory notes issued between July 1, 2016 and December 31, 2016. Lenders earn interest at 2% per annum. The notes mature on December 31, 2017, and at September 30, 2018 the notes were in default. 206,000 206,000 Notes aggregating $1,354,000 issued in the fourth quarter of 2016. The notes accrue interest at 2% per annum and mature between November 1, 2017 and December 31, 2017. As of September 30, 2018 the notes were in default. 1,354,000 1,354,000 Notes aggregating $500,000 issued in the first quarter of 2017. The notes accrue interest at 2% per annum and mature between January 12, 2018 and March 31, 2018. At September 30, 2018, the notes were in default. 500,000 500,000 Promissory note issued January 25, 2017. The lenders earn interest at 7% per month. The note matures on July 5, 2017 and at September 30, 2018 the note was in default. 50,000 50,000 Notes aggregating $300,000 issued in the second quarter of 2017. The notes accrue interest at 2% per annum and mature between April 3, 2018 and May 31, 2018. At September 30, 2018, the notes were in default. 300,000 300,000 Notes aggregating $191,800 issued in the third quarter of 2017. The notes accrue interest at 2% per annum and mature between June 16, 2018 and December 31, 2018. At September 30, 2018, $50,000 of the notes were in default. 191,800 191,800 Promissory note for $425,000 was issued in October 2017 with an original issue discount of $70,000. The note is in default, giving the holder an option to convert the note to stock. In 2018, The defaults also resulted in certain penalties, as a result of which the principal amount of the note outstanding at September 30, 2018 had increased to $500,792. $115,000 of accrued interest owed on the note has been converted to stock. The Company has accrued a $1,448,784 derivative liability for the remaining conversion right. 500,792 425,000 Notes aggregating $105,500 issued in the fourth quarter of 2017. The notes accrue interest at 2% per annum and mature on December 31, 2018. 105,500 105,500 Notes aggregating $47,975 issued in the first quarter of 2018. The notes accrue interest at 2% per annum and mature between May 2018 and January 2019. At September 30, 2018, $10,000 of the notes were in default. 47,975 - Notes aggregating $125,000 issued in the first quarter of 2018. The notes accrue interest between 2% and 12% per annum and mature between April 2018 and June 2018. These notes include warrants between 5,000,000 and 20,000,000 shares with an exercise price of $0.005. At September 30, 2018, the notes were in default. 125,000 - Notes aggregating $65,000 issued in the second quarter of 2018. The notes accrue interest of 2% per annum and mature between July 2018 and October 2018. These notes include warrants between 1,000,000 and 5,000,000 shares with an exercise price of $0.005. At September 30, 2018, the notes were in default. 65,000 - Notes aggregating $193,000 issued in the third quarter of 2018. The notes accrue interest at 2% per annum and mature between November 2018 and January 2019. These notes include warrants between 600,000 and 5,000,000 shares with an exercise price of $0.005. 193,000 - In July 2017, a note for $250,000 was issued. The note earns interest at 5% per annum and matures on November 1, 2018. 250,000 - Less: Original issue discounts on notes payable and warrants issued with notes. (53,500 ) (75,277 ) Total $ 4,795,298 $ 4,820,062

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of the Derivative Liability	The Company estimated the fair value of the derivative liability using the Black-Scholes option pricing model using the following key assumptions during the quarter ended September 30, 2018: Three months ended September 30, Volatility 248 % Risk-free interest rate 1.81 % Expected dividends - % Expected term 1 year
Schedule of Valuation of Financial Instruments	The following schedule summarizes the valuation of financial instruments at fair value in the balance sheets as of September 30, 2018: Fair Value Measurements as of September 30, 2018 Level 1 Level 2 Level 3 Assets None $ - $ - $ - Total assets - - - Liabilities Conversion option derivative liability - - 1,448,784 Total liabilities $ - $ - $ 1,448,784
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	The following table sets forth a reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy: Significant Unobservable Inputs (Level 3) Beginning balance $ 1,669,532 Settlement of liability (243,199 ) Partial settlement of liability (96,091 ) Change in fair value (118,542 ) Ending balance $ 1,448,784

Capital Structure - Common St_2

Capital Structure - Common Stock and Common Stock Purchase Warrants (Tables)	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Schedule of Outstanding Stock Warrants	Following is a summary of outstanding stock warrants at September 30, 2018 and activity during the three months then ended: Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2017 84,287,402 $ 0.01-15.00 $ 0.33 Issued in 2018 141,620,636 $ 0.005-0.20 $ 0.16 Expired and forfeited 410,834 $ 1.50-15.00 $ 6.79 Exercised - $ - - Warrants as of September 30, 2018 225,497,204 $ 0.01-15.00 $ 0.14
Summary of Outstanding Warrants	Summary of outstanding warrants as of September 30, 2018: Expiration Date Number of Shares Exercise Price Remaining Life (years) Fourth Quarter 2018 6,089,166 $ 1.00-1.50 .25 First Quarter 2019 4,024,000 $ 0.50-2.00 .50 Second Quarter 2019 135,000 $ 0.07-0.23 .75 Third Quarter 2019 260,000 $ 0.50-1.50 1.00 Fourth Quarter 2019 22,690,908 $ 0.05-3.74 1.25 Second Quarter 2020 300,000 $ 0.50 1.75 Fourth Quarter 2020 1,000,000 $ 0.20 2.25 First Quarter 2021 12,600,000 $ 0.20 2.50 Second Quarter 2021 5,812,252 $ 0.01-0.20 2.75 Third Quarter 2021 5,116,667 $ 0.03-0.20 3.00 Fourth Quarter 2021 300,000 $ 0.10 3.25 Second Quarter 2022 1,750,000 $ 0.15 3.75 Third Quarter 2022 2,650,000 $ 0.05-0.10 4.00 Fourth Quarter 2022 9,811,422 $ 0.08-0.29 4.25 First Quarter 2023 700,000 $ 0.01-0.03 4.50 Second Quarter 2023 15,000,000 $ 0.01-0.20 4.75 Third Quarter 2023 76,100,000 $ 0.01-0.10 5.00 First Quarter 2024 30,000,000 $ 0.01 5.50 Third Quarter 2028 3,000,000 $ 0.07 10.00 Second Quarter 2032 21,807,789 $ 0.01-0.07 13.75 225,497,204 $ 0.01-15.00

Income Taxes - Results of Ope_2

Income Taxes - Results of Operations (Tables)	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets: September 30, 2018 December 31, 2017 Net operating losses $ 21,319,000 $ 18,102,000 Stock based compensation 39,568,000 39,054,000 Amortization, depreciation, and impairment 4,179,300 4,178,000 Capitalization of start-up costs for tax purposes 1,145,000 1,145,000 Loss on debt conversion of debt 569,000 569,000 Total deferred tax assets 66,780,300 63,048,000 Valuation allowance (66,780,300 ) (63,048,000 ) Total deferred tax assets, net $ - $ -
Schedule of Income Taxes NOL	At December 31, 2017, we had estimated federal and state income tax net operating loss (“NOL”) carry-forwards of approximately $86,000,000, which will expire in 2032-2037. 2018 2017 Amount Percent Amount Percent Benefits for income tax at federal statutory rate $ 212,000 21 % $ 874,000 34 % Permanent differences 173,000 17 % 137,000 - Change in estimates (385,000 ) - (1,011,000 ) - $ - - % $ - - %

Organization and Description _2

Organization and Description of Business (Details Narrative) - USD ($)	Jun. 04, 2018	May 01, 2018	Dec. 08, 2014	Apr. 30, 2016	Dec. 31, 2014	Mar. 31, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Net loss from operations							$ 650,443	$ 1,449,223	$ 3,217,100	$ 4,333,342
Cash and cash equivalents used in operating activities							924,944		924,944	$ 1,615,508
Stockholder's deficit							$ 10,719,477		$ 10,719,477		$ 11,103,386
Cytocom Inc., [Member]
Percentage of sales revenue payable as royalty					5.00%
Issuance of common stock share			140,100,000
Percentage of equity ownership			55.30%				15.95%		15.95%
Reserve stock split description				The Board of Directors and a majority of shareholders of Cytocom approved a reverse stock split of Cytocom's outstanding common stock with one new share of stock for each twenty old shares of common stock. Cytocom effectuated and finalized the reverse split in June 2016.
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%
Cytocom Inc., [Member] | Shareholders [Member]
Issuance of common stock share			113,242,522
Cytocom Inc., [Member] | Maximum [Member]
Percentage of sales revenue payable as royalty		5.00%
Cytocom Inc., [Member] | Minimum [Member]
Percentage of sales revenue payable as royalty		1.00%
Irish Limited Liability [Member]
Percentage of low corporate income tax rate						12.50%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	Jun. 04, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)Segment	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)	Dec. 08, 2014
Maximum of annual gross revenue						$ 1,000,000,000
Federal deposit insurance corporation value		$ 250,000		$ 250,000
Number of operating segment | Segment				1
Depreciation expense		217	$ 269	$ 1,084	$ 557
Accrued interest or penalties related to uncertain tax positions
Property and Equipment [Member] | Minimum [Member]
Property and equipment useful lives				3 years
Property and Equipment [Member] | Maximum [Member]
Property and equipment useful lives				5 years
Cytocom Inc., [Member]
Amount of debt converted into common stock	$ 4,000,000
Percentage of common stock issued in exchange of debt	10.00%
Percentage of equity ownership		15.95%		15.95%			55.30%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Basic Net Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Net Profit/(Loss)	$ (2,602,412)	$ (1,599,842)	$ (7,681,961)	$ (4,157,140)
Weighted-average common shares outstanding, Basic and diluted	407,253,837	341,109,212	396,863,363	301,844,205
Profit/(Loss) per share outstanding, Basic and diluted	$ (0.01)	$ 0	$ (0.02)	$ (0.01)

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Fixed Assets:
Computer equipment	$ 12,997	$ 11,243
Less accumulated depreciation	(9,798)	(8,714)
Fixed assets, net	$ 3,199	$ 2,529

Investments_ Deconsolidation _2

Investments: Deconsolidation of Cytocom (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	May 01, 2018	Dec. 31, 2017
Equity method investments
Notes payable	0
Cytocom Inc., [Member]
Equity method investments		$ 1,189
Loss on investment	0
Notes payable	$ 1,193,500

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued payroll to officers and others	$ 2,212,393	$ 1,539,777
Accrued interest and penalties - notes payable	738,878	703,141
Estimated legal settlements	136,057	136,057
Other accrued liabilities	23,095	393
Estimated loss on note conversions		110,036
Derivative Liability	1,448,784	1,669,532
Total accrued expenses and other liabilities	$ 4,559,207	$ 4,158,936

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt Disclosure [Abstract]
Accrued unpaid interest and default penalties			$ 738,878	$ 594,875
Issuance of common stock for settlement of promissory notes, shares	9,333,143	4,694,017
Issuance of common stock for settlement of promissory notes	$ 111,091	$ 138,843	562,506
Settlement of promissory notes	$ 60,000		$ 60,000

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017	Oct. 31, 2017	Jul. 31, 2016
Total	$ 4,795,298	$ 4,820,063
Less: Original issue discounts on notes payable and warrants issued with notes	(53,500)	(75,277)
Notes Payable One [Member]
Total	100,000	100,000
Notes Payable Two [Member]
Total	286,000	286,000
Notes Payable Three [Member]
Total	475,994	705,994
Notes Payable Four [Member]
Total		425,000
Notes Payable Five [Member]
Total	97,737	97,737
Notes Payable Six [Member]
Total		50,000
Notes Payable Seven [Member]
Total		81,024
Less: Original issue discounts on notes payable and warrants issued with notes				$ (30,000)
Notes Payable Eight [Member]
Total		17,284
Notes Payable Nine [Member]
Total	206,000	206,000
Notes Payable Ten [Member]
Total	1,354,000	1,354,000
Notes Payable Eleven [Member]
Total	500,000	500,000
Notes Payable Twelve [Member]
Total	50,000	50,000
Notes Payable Thirteen [Member]
Total	300,000	300,000
Notes Payable Fourteen [Member]
Total	191,800	191,800
Notes Payable Fifteen [Member]
Total	500,792	425,000
Less: Original issue discounts on notes payable and warrants issued with notes			$ (70,000)
Notes Payable Sixteen [Member]
Total	105,500	105,500
Notes Payable Seventeen [Member]
Total	47,975
Notes Payable Eighteen [Member]
Total	125,000
Notes Payable Nineteen [Member]
Total	65,000
Notes Payable Twenty [Member]
Total	193,000
Notes Payable Twenty One [Member]
Total	$ 250,000

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)	Jan. 25, 2017	Aug. 31, 2016USD ($)Installments	Jul. 31, 2016USD ($)	Nov. 03, 2015	Dec. 08, 2014shares	Jul. 29, 2014	Jul. 31, 2018USD ($)	Jul. 31, 2017USD ($)	Jul. 31, 2016USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Dec. 31, 2016USD ($)	Jun. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)Doses	Dec. 31, 2016USD ($)	Oct. 31, 2017USD ($)
Accrued interest										$ 738,878						$ 738,878		$ 703,141
Original issuance discount										$ 53,500						53,500		$ 75,277
Debt conversion converted instrument, shares issued | shares										9,333,143		4,694,017
Number of shares converted into common stock										$ 111,091		$ 138,843				562,506
Cytocom Inc., [Member]
Number of shares issued | shares					140,100,000
Notes Payable Two [Member]
Percentage of interest rate per annum															10.00%					10.00%
Number of installments, months | Doses																				36
Notes Payable Two [Member] | Maximum [Member]
Maximum amount raise in debt															$ 2,000,000					$ 2,000,000
Notes Payable Four [Member] | Cytocom Inc., [Member]
Note matures date															Dec. 31, 2016
Notes Payable Four [Member] | Maximum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum															10.00%					10.00%
Notes Payable Four [Member] | Minimum [Member] | Cytocom Inc., [Member]
Percentage of interest rate per annum															5.00%					5.00%
Notes Payable Five [Member]
Note matures date				Nov. 3, 2016
Percentage of interest rate per annum				10.00%
Notes Payable Six [Member]
Note matures date									Oct. 5, 2016
Percentage of interest rate per annum			6.00%						6.00%
Note extended date									Dec. 31, 2016
Notes Payable Seven [Member]
Note matures date			Apr. 7, 2017
Percentage of interest rate per annum																		25.00%
Accrued interest																		$ 20,025
Notes aggregating default amount			$ 180,000						$ 180,000									$ 161,976
Original issuance discount			$ 30,000						$ 30,000
Debt conversion converted instrument, shares issued | shares																		7,447,448
Number of shares issued | shares																		5,500,000
Derivative liability																		$ 243,199
Principal balance attributable to the conversion feature																		81,024
Notes Payable Seven [Member] | Maximum [Member]
Notes aggregating default amount																		$ 243,000
Notes Payable Eight [Member]
Percentage of interest rate per annum		5.00%
Number of installments, months | Installments		18
Notes aggregating default amount		$ 149,854
Debt instrument, periodic payment, principal		$ 8,642
Notes Payable Nine [Member] | Lenders [Member]
Note matures date																			Dec. 31, 2017
Percentage of interest rate per annum													2.00%						2.00%		2.00%
Notes Payable Ten [Member]
Percentage of interest rate per annum													2.00%						2.00%		2.00%
Debt instrument maturity date description													November 1, 2017 and December 31, 2017
Notes aggregating default amount													$ 1,354,000						$ 1,354,000		$ 1,354,000
Notes Payable Eleven [Member]
Percentage of interest rate per annum												2.00%					2.00%
Debt instrument maturity date description																	January 12, 2018 and March 31, 2018
Notes aggregating default amount												$ 500,000					$ 500,000
Notes Payable Thirteen [Member]
Percentage of interest rate per annum												2.00%					2.00%
Debt instrument maturity date description												April 3, 2018 and May 31, 2018
Notes aggregating default amount												$ 300,000					$ 300,000
Notes Payable Fourteen [Member]
Percentage of interest rate per annum												2.00%					2.00%
Debt instrument maturity date description												June 16, 2018 and December 31, 2018
Notes aggregating default amount										50,000		$ 191,800				50,000	$ 191,800
Notes Payable Fifteen [Member]
Accrued interest										500,792						500,792
Notes aggregating default amount																						$ 425,000
Original issuance discount																						$ 70,000
Derivative liability										1,448,784						1,448,784
Number of shares converted into common stock																115,000
Notes Payable Sixteen [Member]
Percentage of interest rate per annum												2.00%					2.00%
Debt instrument maturity date description												December 31, 2018
Notes aggregating default amount												$ 105,500					$ 105,500
Notes Payable Seventeen [Member]
Percentage of interest rate per annum											2.00%
Maximum amount raise in debt										$ 10,000						$ 10,000
Debt instrument maturity date description											May 2018 and January 2019
Notes aggregating default amount											$ 47,975
Notes Payable Eighteen [Member]
Debt instrument maturity date description											April 2018 and June 2018
Notes aggregating default amount											$ 125,000
Warrant exercise price per share | $ / shares											$ 0.005
Notes Payable Eighteen [Member] | Maximum [Member]
Percentage of interest rate per annum											12.00%
Number of warrants | shares											20,000,000
Notes Payable Eighteen [Member] | Minimum [Member]
Percentage of interest rate per annum											2.00%
Number of warrants | shares											5,000,000
Notes Payable Nineteen [Member]
Percentage of interest rate per annum														2.00%
Debt instrument maturity date description														July 2018 and October 2018
Notes aggregating default amount														$ 65,000
Warrant exercise price per share | $ / shares														$ 0.005
Notes Payable Nineteen [Member] | Maximum [Member]
Number of warrants | shares														5,000,000
Notes Payable Nineteen [Member] | Minimum [Member]
Number of warrants | shares														1,000,000
Notes Payable Twenty [Member]
Percentage of interest rate per annum										2.00%						2.00%
Debt instrument maturity date description										November 2018 and January 2019
Notes aggregating default amount										$ 193,000						$ 193,000
Warrant exercise price per share | $ / shares										$ 0.005						$ 0.005
Notes Payable Twenty [Member] | Maximum [Member]
Number of warrants | shares										5,000,000						5,000,000
Notes Payable Twenty [Member] | Minimum [Member]
Number of warrants | shares										600,000						600,000
Notes Payable Twenty One [Member]
Note matures date								Nov. 1, 2018
Percentage of interest rate per annum								5.00%
Notes aggregating default amount								$ 250,000
Ira Gaines [Member] | Notes Payable One [Member]
Note matures date						Dec. 1, 2017
Percentage of interest rate per annum						18.00%
Lenders [Member] | Notes Payable Three [Member]
Maximum amount raise in debt										$ 130,000						$ 130,000
Debt instrument maturity date description																					June 14, 2015 and December 1, 2017
Aggregating loan													375,994						375,994		$ 375,994
Accrued interest													$ 100,000						$ 100,000		$ 100,000
Notes aggregating default amount										$ 475,994						$ 475,994
Debt, current							$ 100,000
Extinguishment of debt, amount							$ 150,000
Lenders [Member] | Notes Payable Three [Member] | Maximum [Member]
Percentage of interest rate per annum													18.00%						18.00%		18.00%
Lenders [Member] | Notes Payable Three [Member] | Minimum [Member]
Percentage of interest rate per annum													2.00%						2.00%		2.00%
Lenders [Member] | Notes Payable Twelve [Member]
Note matures date	Jul. 5, 2017
Percentage of interest rate per annum	7.00%

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Notes payable	$ 0
Derivative liabilities	1,448,784	$ 1,669,532
Other Notes Payable [Member]
Converted derivative liability	60,000
Derivative liabilities	623,045
Revalue of derivative liabilities	$ 1,448,784

Derivative Liabilities - Schedu

Derivative Liabilities - Schedule of Estimated Fair Value of the Derivative Liability (Details) - Black-Scholes Option Pricing Model [Member]	3 Months Ended
	Sep. 30, 2018
Volatility [Member]
Fair value assumptions, measurement input, percentages	248.00%
Risk-Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	1.81%
Expected Dividends [Member]
Fair value assumptions, measurement input, percentages	0.00%
Expected Term [Member]
Fair value assumptions, measurement input, term	1 year

Derivative Liabilities - Sche_2

Derivative Liabilities - Schedule of Valuation of Financial Instruments (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Total assets	$ 167,906	$ 195,545
Total liabilities	10,887,383	$ 11,298,931
Level 1 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 2 [Member]
Total assets
Conversion option derivative liability
Total liabilities
Level 3 [Member]
Total assets
Conversion option derivative liability	1,448,784
Total liabilities	$ 1,448,784

Derivative Liabilities - Sche_3

Derivative Liabilities - Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details)	9 Months Ended
	Sep. 30, 2018USD ($)
Derivative liabilities beginning balance	$ 1,669,532
Derivative liabilities ending balance	1,448,784
Level 3 [Member]
Derivative liabilities beginning balance	1,669,532
Settlement of liability	(243,199)
Partial settlement of liability	(96,091)
Change in fair value	(118,542)
Derivative liabilities ending balance	$ 1,448,784

Capital Structure - Common St_3

Capital Structure - Common Stock and Common Stock Purchase Warrants (Details Narrative) - $ / shares	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Equity [Abstract]
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares outstanding	415,661,456	386,782,473
Number of warrants issued during period	80,550,000

Capital Structure - Common St_4

Capital Structure - Common Stock and Common Stock Purchase Warrants - Schedule of Outstanding Stock Warrants (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Shares Warrants, Beginning balance | shares	84,287,402
Number of Shares Warrants, Issued | shares	141,620,636
Number of Shares Warrants, Expired and forfeited | shares	410,834
Number of Shares Warrants, Exercised | shares
Number of Shares Warrants, Ending balance | shares	225,497,204
Exercise Price, Exercised
Weighted average exercise price, Beginning balance	0.33
Weighted average exercise price, Issued	0.16
Weighted average exercise price, Expired and forfeited	6.79
Weighted average exercise price, Exercised
Weighted average exercise price, Ending balance	0.14
Minimum [Member]
Exercise Price, Beginning balance	0.01
Exercise Price, Issued	0.005
Exercise Price, Expired and forfeited	1.50
Exercise Price, Ending balance	0.01
Maximum [Member]
Exercise Price, Beginning balance	15
Exercise Price, Issued	0.20
Exercise Price, Expired and forfeited	15
Exercise Price, Ending balance	$ 15

Capital Structure - Common St_5

Capital Structure - Common Stock and Common Stock Purchase Warrants - Summary of Outstanding Warrants (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Shares | shares	225,497,204
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 15
Fourth Quarter 2018 [Member]
Number of Shares | shares	6,089,166
Exercise Price Lower Limit	$ 1
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	2 months 30 days
First Quarter 2019 [Member]
Number of Shares | shares	4,024,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 2
Remaining Life (years)	6 months
Second Quarter 2019 [Member]
Number of Shares | shares	135,000
Exercise Price Lower Limit	$ 0.07
Exercise Price Upper Limit	$ 0.23
Remaining Life (years)	9 months
Third Quarter 2019 [Member]
Number of Shares | shares	260,000
Exercise Price Lower Limit	$ 0.50
Exercise Price Upper Limit	$ 1.50
Remaining Life (years)	1 year
Fourth Quarter 2019 [Member]
Number of Shares | shares	22,690,908
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 3.74
Remaining Life (years)	1 year 2 months 30 days
Second Quarter 2020 [Member]
Number of Shares | shares	300,000
Exercise Price Upper Limit	$ 0.50
Remaining Life (years)	1 year 9 months
Fourth Quarter 2020 [Member]
Number of Shares | shares	1,000,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 2 months 30 days
First Quarter 2021 [Member]
Number of Shares | shares	12,600,000
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 6 months
Second Quarter 2021 [Member]
Number of Shares | shares	5,812,252
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	2 years 9 months
Third Quarter 2021 [Member]
Number of Shares | shares	5,116,667
Exercise Price Lower Limit	$ 0.03
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	3 years
Fourth Quarter 2021 [Member]
Number of Shares | shares	300,000
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	3 years 2 months 30 days
Second Quarter 2022 [Member]
Number of Shares | shares	1,750,000
Exercise Price Upper Limit	$ 0.15
Remaining Life (years)	3 years 9 months
Third Quarter 2022 [Member]
Number of Shares | shares	2,650,000
Exercise Price Lower Limit	$ 0.05
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	4 years
Fourth Quarter 2022 [Member]
Number of Shares | shares	9,811,422
Exercise Price Lower Limit	$ 0.08
Exercise Price Upper Limit	$ 0.29
Remaining Life (years)	4 years 2 months 30 days
First Quarter 2023 [Member]
Number of Shares | shares	700,000
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.03
Remaining Life (years)	4 years 6 months
Second Quarter 2023 [Member]
Number of Shares | shares	15,000,000
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.20
Remaining Life (years)	4 years 9 months
Third Quarter 2023 [Member]
Number of Shares | shares	76,100,000
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.10
Remaining Life (years)	5 years
First Quarter 2024 [Member]
Number of Shares | shares	30,000,000
Exercise Price Upper Limit	$ 0.01
Remaining Life (years)	5 years 6 months
Third Quarter 2028 [Member]
Number of Shares | shares	3,000,000
Exercise Price Upper Limit	$ 0.07
Remaining Life (years)	10 years
Second Quarter 2032 [Member]
Number of Shares | shares	21,807,789
Exercise Price Lower Limit	$ 0.01
Exercise Price Upper Limit	$ 0.07
Remaining Life (years)	13 years 9 months

Stock Compensation (Details Nar

Stock Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018
Number of common stock issued for consulting fees	7,500,000	1,700,000
Number of common stock issued for consulting fees, value	$ 190,000	$ 61,000
Amortization of prepaid services	$ 0	$ 446,002
Minimum [Member]
Consulting fees amortized period			12 months
Maximum [Member]
Consulting fees amortized period			24 months

Income Taxes - Results of Ope_3

Income Taxes - Results of Operations (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income tax examination, description	The impact of U.S. Tax Reform primarily represents the Company's estimates of revaluing the Company's U.S. deferred tax assets and liabilities based on the rates at which they are expected to be recognized in the future. For U.S. federal purposes the corporate statutory income tax rate was reduced from 35% to 21%
Percentage of statutory income tax rate	21.00%	34.00%
Lower corporate tax rate	21.00%
Effective tax rate	0.00%	0.00%
Operating loss carryforwards			$ 86,000,000
Operating loss carryforwards expire term	expire in 2032-2037

Income Taxes - Results of Ope_4

Income Taxes - Results of Operations - Schedule of Deferred Tax Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating losses	$ 21,319,000	$ 18,102,000
Stock based compensation	39,568,000	39,054,000
Amortization, depreciation, and impairment	4,179,300	4,178,000
Capitalization of start-up costs for tax purposes	1,145,000	1,145,000
Loss on debt conversion of debt	569,000	569,000
Total deferred tax assets	66,780,300	63,048,000
Valuation allowance	(66,780,300)	(63,048,000)
Total deferred tax assets, net

Income Taxes - Results of Ope_5

Income Taxes - Results of Operations - Schedule of Income Taxes NOL (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Benefits for income tax at federal statutory rate			$ 212,000	$ 874,000
Permanent differences			173,000	137,000
Change in estimates			(385,000)	(1,011,000)
Net operating loss
Benefits for income tax at federal statutory rate, percent			21.00%	34.00%
Permanent differences, percent			17.00%	0.00%
Change in estimates, percent			0.00%	0.00%
Effective income tax rate reconciliation, percent			0.00%	0.00%

Licenses and Supply Agreements

Licenses and Supply Agreements (Details Narrative) - USD ($)	May 01, 2018	Apr. 24, 2012
Cytocom Inc., [Member] | Maximum [Member]
Royalty percentage	5.00%
Cytocom Inc., [Member] | Minimum [Member]
Royalty percentage	1.00%
TNI BioTech IP, Inc. [Member]
Number of shares acquired in exchange for common stock		20,250,000
Acquisition value		$ 98,000,000
Dr. Plotnikoff [Member]
Number of shares acquired in exchange for common stock		8,000,000
TNI IP's Management [Member]
Number of shares acquired in exchange for common stock		12,250,000
Acquisition value		$ 16,006,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Apr. 18, 2018	May 16, 2016	Oct. 31, 2013	Sep. 30, 2018	Sep. 30, 2017
Cash rental expense				$ 2,238	$ 12,632
Complete Pharmacy and Medical Solutions, LLC [Member]
Ramp up costs, percentage		100.00%
AHAR Pharma [Member]
Distribution agreement, description	In October 2018, the Company shipped 250,000 pills to Fidson to support the product launch in the coming months.		The Company is obligated to provide delivery of an initial supply of between 1 million and 1.5 million doses of Lodonal™ product to cover AHAR Pharma's first-year purchase commitment.

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended
	Nov. 14, 2018	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Debt conversion converted instrument, shares issued		9,333,143	4,694,017
Common stock, shares outstanding		415,661,456		386,782,473
Subsequent Event [Member]
Number of common stock shares issued	18,661,118
Debt conversion converted instrument, shares issued	12,411,118
Consulting fees	$ 6,250,000
Common stock, shares outstanding	434,322,060
Increased in debt and equity finance	$ 15,500